Literature DB >> 9681506

Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells.

C P Tseng1, B D Ely, Y Li, R C Pong, J T Hsieh.   

Abstract

Androgen is a mitogen as well as a morphogen for prostatic epithelium. However, the detailed mechanisms of these distinct androgenic actions have not yet been delineated. Therefore, we employed differential display PCR to unveil any potential genes that may be involved in these processes. In this study, we report the isolation and characterization of two alternative splicing forms (p82 and p59) of C9 complementary DNA, the rat homolog of the human deletion of ovarian carcinoma 2 (DOC-2) gene and mouse p96 phosphoprotein, from rat ventral prostate (VP). We found that C9 was up-regulated in rat VP after castration, suggesting that C9 may be regulated by androgen receptor directly or indirectly during prostate degeneration. A similar regulatory pattern was also observed in both the seminal vesicle and dorsolateral prostate, but not in the coagulating gland or other androgen-independent organs. Immunohistochemical analysis of rat VP demonstrated that C9 is detected in the basal epithelia and surrounding stromal cells after prolonged castration. Ribonuclease protection assay and Western blot analysis revealed that p59 is the predominant C9 isoform in rat VP. To unveil the function of C9 in cell growth, we transfected p59 complementary DNA into the C4-2 cells, a derivative of the LNCaP prostatic carcinoma cell line. The p59 stable transfectants exhibited a slower growth rate and an increase in the cell fraction in the G1 phase under our experimental conditions. These data indicate that C9-p59 has growth inhibitory activity for prostatic epithelial cells. Taken together, our results suggest that C9 is up-regulated during prostate degeneration process and may play an active role in the proliferation and differentiation of prostatic epithelium.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681506     DOI: 10.1210/endo.139.8.6159

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  29 in total

Review 1.  Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis.

Authors:  Beata Pyrzynska; Iwona Pilecka; Marta Miaczynska
Journal:  Mol Oncol       Date:  2009-06-11       Impact factor: 6.603

2.  Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background.

Authors:  Dong-Hua Yang; Zia Fazili; Elizabeth R Smith; Kathy Qi Cai; Andres Klein-Szanto; Cynthia Cohen; Ira R Horowitz; Xiang-Xi Xu
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Authors:  Adèle Hannigan; Paul Smith; Gabriela Kalna; Cristiana Lo Nigro; Clare Orange; Darren I O'Brien; Reshma Shah; Nelofer Syed; Lindsay C Spender; Blanca Herrera; Johanna K Thurlow; Laura Lattanzio; Martino Monteverde; Meghan E Maurer; Francesca M Buffa; Jelena Mann; David C K Chu; Catharine M L West; Max Patridge; Karin A Oien; Jonathan A Cooper; Margaret C Frame; Adrian L Harris; Louise Hiller; Linda J Nicholson; Milena Gasco; Tim Crook; Gareth J Inman
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

4.  p67 isoform of mouse disabled 2 protein acts as a transcriptional activator during the differentiation of F9 cells.

Authors:  S Y Cho; J W Jeon; S H Lee; S S Park
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

5.  Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport.

Authors:  Shelli M Morris; Michelle D Tallquist; Charles O Rock; Jonathan A Cooper
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

6.  Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.

Authors:  Joanna H Tong; David C Ng; Shuk L Chau; Ken K So; Patrick P Leung; Tin L Lee; Raymond W Lung; Michael W Chan; Anthony W Chan; Kwok W Lo; Ka F To
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

7.  Type II transforming growth factor-beta receptor recycling is dependent upon the clathrin adaptor protein Dab2.

Authors:  Sumedha G Penheiter; Raman Deep Singh; Claire E Repellin; Mark C Wilkes; Maryanne Edens; Philip H Howe; Richard E Pagano; Edward B Leof
Journal:  Mol Biol Cell       Date:  2010-09-29       Impact factor: 4.138

8.  Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.

Authors:  Yi Lu; Xiongwen Zhang; Ben Beheshti; Jun Zhang
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

9.  Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis.

Authors:  C Puri; M V Chibalina; S D Arden; A J Kruppa; J Kendrick-Jones; F Buss
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

10.  Sulfatides partition disabled-2 in response to platelet activation.

Authors:  Karen E Drahos; John D Welsh; Carla V Finkielstein; Daniel G S Capelluto
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.